Présentation de l'entreprise
Ascendis Pharma A/S operates within the healthcare sector, specifically functioning as a biotechnology firm dedicated to developing TransCon-based therapies designed to address unmet medical needs across Europe, the United States, and international markets. The company's core portfolio includes SKYTROFA, which treats pediatric patients with growth hormone deficiency, and YORVIPATH, an oncology therapy. As of the latest data, the enterprise holds a substantial market capitalization of $14.32B and generates annual revenue of $720.13M, supported by a workforce of 1189 employees. These valuation and revenue figures position Ascendis Pharma as a significant entity within the biotechnology industry, reflecting a large-scale operation that commands considerable investor attention despite its current financial structure. The scale of the market cap relative to its revenue suggests the market values the company's future therapeutic potential and intellectual property significantly higher than its current cash-generating capabilities alone would justify.
Santé financière
The company reported a revenue of $720.13M for the trailing twelve months, yet it recorded a net income of $-228,034,000 and an EBITDA of $-131,415,000, highlighting a substantial gap between top-line growth and bottom-line profitability. This disparity reveals a cost structure where research, development, and operational expenses far exceed current earnings, a common characteristic in the early-to-mid stages of biotechnology growth. Despite the reported net loss, the firm maintains positive free cash flow of $164.71M, which indicates a degree of financial flexibility allowing the company to fund operations and R&D without immediate reliance on external equity financing. The gross margin stands at an impressive 86.8%, while the operating margin is 1.0% and the profit margin is -31.7%, demonstrating that high production efficiency is being offset by significant non-operating costs or R&D amortization. On the balance sheet, Ascendis Pharma holds $616.04M in cash against $871.79M in debt, resulting in a negative price-to-book ratio of -75.95 and a debt-to-equity ratio that is not applicable due to the company's negative equity position. The current ratio of 1.04 suggests that the company's short-term liquid assets are slightly above its short-term liabilities, indicating a manageable but tight liquidity position. Return on Equity is not applicable, while the return on assets stands at -6.9%, signaling that management is currently generating negative returns on its asset base as it invests heavily in pipeline development.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is not applicable given the negative earnings, whereas the forward P/E is 18.90, implying that the market expects significant earnings turnaround or normalization in the future to justify the current valuation multiple. The price-to-book ratio is -75.95, which indicates that the stock is trading at a substantial discount relative to its book value, a typical metric for growth biotechs that prioritize reinvestment over current asset valuation. Alternative valuation metrics such as the price-to-sales ratio of 19.88 and an EV/EBITDA of -110.87 suggest that investors are pricing the company primarily on revenue growth potential rather than current profitability or cash flow generation. Over the past year, the stock has traded between a 52-week low of $124.06 and a 52-week high of $248.60; the current price sits dynamically within this range, reflecting the volatility inherent in biotechnology equities with late-stage pipelines. The stock exhibits a beta of 0.48, indicating that its price volatility is significantly lower than the broader market, suggesting a defensive characteristic relative to the high-beta nature of the overall biotechnology sector.
Growth & Income
Ascendis Pharma reported a revenue growth of 42.3% year-over-year, while earnings growth is not applicable due to the company's continued net losses, implying that top-line expansion is the primary driver of current value creation rather than profit scaling. As a non-dividend payer, the company maintains a dividend yield of not applicable and a payout ratio of 0.0%, confirming that all available earnings and cash flow are reinvested into research, development, and commercialization efforts rather than distributed to shareholders. This reinvestment strategy is consistent with the company's stage of development, where capital allocation towards pipeline advancement is prioritized over immediate income generation for investors. The overall growth and income profile presents a high-risk, high-reward dynamic characterized by rapid revenue expansion and zero dividend income, relying entirely on future product approvals and commercial success to eventually convert current losses into sustainable profitability.